| 764258 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
212 Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates |
2021-11-01 |
10.1136/jitc-2021-sitc2021.212 |
Nash Amanda, Jarvis Maria, Aghlara-Fotovat Samira, Mukherjee Sudip, Hernandez Andrea, Hecht Andrew, Rios Peter, Ghani Sofia, Joshi Ira, Isa Douglas, Cui Yufei, Nouraein Shirin, Lee Jared, Xu Chunyu, Zhang David, Sheth Rahul, Peng Weiyi, Oberholzer Jose, Igoshin Oleg, Jazaeri Amir, Veiseh Omid |
| 764257 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
208 RTX-224, an engineered allogeneic red cell therapeutic expressing 4–1BBL and IL-12, activates immune cells in blood and spleen to promote tumor growth inhibition in mice |
2021-11-01 |
10.1136/jitc-2021-sitc2021.208 |
Dugast Anne-Sophie, McArdel Shannon, Castano Zafira, Hoover Maegan, Bollampalli Arjun Reddy, Hong Enping, Leonard Shannon, Pepi Ryan, Nanna Alex, Turka Laurence, Elloul Sivan |
| 764256 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
960 Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.960 |
Rahma Osama, Katz Mathew, Bauer Todd, Wolpin Brian, Stucky Chee-Chee, Bekaii-Saab Tanios, Elias Rawad, Dias-Costa Andressa, Nowak Jonathan, Patrick Lenehan, Petroni Gina, Dougan Stephanie, Slingluff Craig |
| 764255 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.959 |
Wermke Martin, Tsimberidou Apostolia-Maria, Mohamed Ali, Mayer-Mokler Andrea, Satelli Arun, Reinhardt Carsten, Araujo Dejka, Maurer Dominik, Blumenschein George Jr, Singh Harpreet, Luke Jason, Guenther Kerstin, Kalra Mamta, Chatterjee Manik, Hilf Norbert, Mendrzyk Regina, Walter Steffen, Eck Stephen, Holderried Tobias AW, Weinschenk Toni, Morris Van, Alsdorf Winfried, Britten Cedrik M |
| 764254 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.958 |
Mackensen Andreas, Koenecke Christian, Haanen John, Alsdorf Winfried, Desuki Alexander, Wagner-Drouet Eva, Heudobler Daniel, Borchmann Peter, Wiegert Erol, Schulz Catrine, Rengstl Benjamin, Preussner Liane, Tuereci Oezlem, Sahin Ugur |
| 764253 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.957 |
Altan Mehmet, Patnaik Amita, Barve Minal, Dunn Lara, Cobb Patrick, Rosenberg Ari, Sharma Sunil, Sukari Ammar, Patel Manish, Wang Xiaoli, Ma Haijun, Dixit Neha, Nieves Wildaliz, Fanton Christie, Currie Sue, Lee Zachary, Marcondes Mario, Zalevsky Johnathan, Tagliaferri Mary, Sacco Assuntina |
| 764252 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
956 Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: results from the POD1UM-101 study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.956 |
Berton Dominique, Pautier Patricia, Lorusso Domenica, Gennigens Christine, Gladieff Laurence, Kryzhanivska Anna, Ranganathan Sulabha, Tian Chuan, Bourayou Nawel, Vergote Ignace |
| 764251 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.955 |
Li Roger, Steinberg Gary, Lamm Donald, Uchio Ed, Packiam Vignesh, Kamat Ashish, Chisamore Michael, McAdory John, Grandi Paola, Kim Jee-Hyun, Burke James |
| 764250 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus |
2021-11-01 |
10.1136/jitc-2021-sitc2021.954 |
Brachtlova Tereza, Abramovitch Allan, Giddens Jonathan, Incze Peter, Jansz Kenneth, Casey Richard, Beusechem Victor van, Dong Wenliang |
| 764249 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
953 Transcriptional analysis of leukocytes from COVID convalescent donors reveals persistent activation of the innate and adaptive immune system |
2021-11-01 |
10.1136/jitc-2021-sitc2021.953 |
Gedda Mallikarjuna, Danaher Patrick, Saho Lipei, Ongkeko Martin, Chen Leonard, Sall Mame Thioye, Reddy Opal, Bailey Christina, Wahba Amy, Dzekunova Inna, Giorgi Valeria De, Somerville Robert, Ping Jin, West Kamille, Panch Sandhya, Stroncek David |
